- Home
- J&J Innovative Medicine
J&J Innovative Medicine
Using your own cells to fight cancer
Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson has treated more than 10,000 patients and counting with this cutting-edge therapy.
“I refuse to let lupus get me down”
Diagnosed with systemic lupus erythematosus (SLE) almost two decades ago, Laurie Bean has chosen a lifestyle that helps her battle debilitating side effects and the emotional fallout of this autoantibody disease.
What is a gene mutation?
Experts aren’t sure why, but sometimes changes in DNA can trigger cancer to grow and spread. Learn all about gene mutations—and Johnson & Johnson’s work developing new therapies to target these specific types of cancer.
“Reimagining what life with schizophrenia could look like”
Johnson & Johnson’s Leonardo Diaz, M.D., addresses common misconceptions about schizophrenia, the critical importance of preventing relapse and why there’s so much optimism about treatments.
What you need to know about Johnson & Johnson’s first-quarter 2026 earnings report
Check out this infographic breakdown of the company’s first-quarter performance, with highlights from its Innovative Medicine and MedTech businesses.
6 ways Johnson & Johnson is using AI to help advance healthcare
Artificial intelligence is revolutionizing healthcare—from improving surgical training and procedures to equipping healthcare providers with insights and personalizing care for patients around the world. See how the company is harnessing its extraordinary power.
What are alloantibodies?
Learn how Johnson & Johnson is investigating a therapy for two alloantibody-driven diseases that can affect the lives of developing fetuses and newborn babies.
5 things we now know about plaque psoriasis
Plaque psoriasis is the most prevalent form of psoriasis, affecting millions worldwide. Johnson & Johnson is focused on developing novel therapies for chronic dermatologic diseases to address the unmet need that still exists.
Getting in front of cancer
Every year, roughly 2 million people in the U.S. are newly diagnosed with cancer. But new scientific breakthroughs—including ones made at Johnson & Johnson—have dramatically changed the prognosis of many of these patients.
“My company makes the medication that helped me fight multiple myeloma”
Paul Reidy, a Johnson & Johnson warehouse technician in Ireland, never imagined that an oncology therapy made at the facility where he works would help save his life.